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ABSTRACT 
 
 
Background and Objectives: Leptospirosis is a zooanthroponosis caused by the genus of Leptospira. It is an emerging 
public health problem due to its increasing incidence. The achievement to a vaccine that prevent from entrance of Leptospira 
interrogans to the deeper tissues of the host is needed. This study aimed to investigate the immunogenicity of LcpA (rLcpA) 
and LenA (rLenA) recombinant proteins in combination with LTB (rLTB) recombinant protein as an adjuvant against lepto- 
spiral infection in hamsters. 
Materials and Methods: The genes encoding these proteins were cloned into pGH cloning vector and then lenA, lcpA and 
ltb genes subcloned into pET-15b and pET-28a expression vectors, respectively. The hamsters were immunized with the puri- 
fied recombinant proteins and challenged with Leptospira interrogans for evaluation of their survival. The antibody respons- 
es to the recombinant proteins were determined by ELISA. Then, data entered into SPSS software. Statistical Kruskal–Wallis 
test was used to compare the significant differences among different groups. The groups with significant differences were 
further analyzed by post hoc tests. The p value < 0.05 statistically was considered significant. 
Results: Immunized hamsters with rLenA-plus-rLTB, rLcpA-plus-rLTB and rLenA-plus-rLcpA-plus-rLTB proteins showed 
60%, 74%, and 80% survival rates, respectively. A significant amount of interleukin-17 (IL-17), interleukin-4 (IL-4) and 
gamma interferon (IFNγ) cytokines were produced in immunized hamsters. 
Conclusion: Based on our findings, rLcpA and rLenA proteins in combination with rLTB can protect the hamsters against 
L. interrogans and effectively induce a protective antibody response. Thus, these proteins can be used as an additional pro- 
phylactic tool against leptospira. 
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INTRODUCTION 
 
Leptospirosis is an emerging global zoonotic dis- 
ease, caused by pathogenic bacteria belonging to the 
genus Leptospira (1). Large outbreaks of leptospirosis 
have recently occurred in many countries, especially 
in South-East Asian region and in South America (2). 
Pathogenic Leptospira species are invasive and have 
the ability to colonize and invade the renal tubules of 
incidental hosts like rodents, dogs, cats, cattle, pigs, 
and horses, presenting with variable clinical symp- 
toms (3). Clinical manifestations are ranging from 
a mild febrile illness to severe disease that can in- 
clude fever, headache, vomiting, diarrhea, anorexia, 
muscle pain and constipation (4, 5). The adhesion of 
pathogenic Leptospira to the mucous membrane of 
the hosts was considered to be essential during the 
early stage of the infection (6). 
There is an urgent need to explore alternative strat- 
egies against leptospiral infections, including vac- 
cine production. The currently available leptospiral 
vaccines are based on inactivated Leptospiral whole 
cell or membrane preparations of the pathogenic and 
have low efficacy. However, these vaccines stimulate 
antibody responses against leptospiral lipopolysac- 
charide, but do not provide cross-protective immuni- 
ty against leptospiral serovars and generally produce 
only short-term immunity in domestic livestock (7, 
8). So far, a large number of pathogenic and sapro- 
phytic serovars (>320) of Leptospira species have 
been described, which is a major limitation to the 
production of a multi-protein vaccine against multi- 
ple Leptospira serovars and development of immu- 
nization protocols based on whole cell or membrane 
preparations (9, 10). Moreover, due to lack of protec- 
tion among carriage, hosts will shed the bacteria in 
their urine and contaminate the environments (11). 
Based on previous studies, several promising vac- 
cine candidates are under evaluation. A human vac- 
cine has been developed in China, but this vaccine is 
not protective in children under 14 years. A vaccine 
licensed for the human is still in experimental stage 
and therefore not approved for human usage (7, 12). 
After whole genome sequencing of Leptospira spe- 
cies, a large number of leptospiral virulence factors, 
and surface proteins have been identified to repre- 
sent new potential targets for the development of an- 
ti-leptospiral drug, vaccine and diagnostic strategies. 
Leptospira species express several outer surface pro- 
teins that may be promising candidates for the de- 
velopment of vaccines against leptospiral infections. 
LenA and LcpA proteins have been characterized as 
potential virulence factors. LcpA (leptospiral com- 
plement regulator-acquiring protein A) is a surface 
protein  that  binds  both  purified and  soluble  C4b 
binding protein (C4BP) from human sera (13). This 
protein is an outer membrane protein and contributes 
to pathogenic Leptospira immune evasion by bind- 
ing to the complement system inhibitors (14). Based 
on previous studies, LcpA is found in serum resis- 
tance pathogenic Leptospira but not in non-patho- 
genic strains (15). LenA is a member of the lepto- 
spiral endostatin-like (Len) protein family, which 
interact with extracellular matrix (ECM), plasmino- 
gen (PLG), fibronectin, laminin, complement factor 
H and factor H-related protein-1 (3, 11). The genes 
coding for LcpA and LenA proteins are conserved 
among pathogenic strains of Leptospira (6). 
To the best of our knowledge, no appropriate pro- 
phylactic studies on these leptospiral proteins have 
been reported. The effectiveness of these proteins in 
combination with LTB as an adjuvant remains to be 
evaluated. With the goal of discovering a new vac- 
cine, the rLcpA, rLenA and rLTB recombinant pro- 
teins were produced in Escherichia coli BL21 (DE3) 
cells and their immunogenic potentials were consid- 
ered in animal model. 
 
 
 
MATERIALS AND METHODS 
 
Cloning, expression and purification of recom- 
binant proteins. Genomic DNAs of L. interrogans 
serovar Copenhageni strain Fiocruz L1-130 and 
ETEC  (Enterotoxigenic  Escherichia  coli)  ATCC 
35401 were extracted using DNA extraction kit (Qia- 
gen, Germany) according to the manufacturer’s in- 
structions. The extracted DNAs were stored at -20°C 
until the proper time for the experiments. Amplifi- 
cation of lcpA, lenA and ltb genes was carried out 
using specific forward and reverse primers, as shown 
in Table 1. Following enzyme digestion of gene am- 
plicons and vectors carried out with restriction en- 
zymes XhoI/HindIII (for lcpA gene), NdeI/XhoI (for 
LenA gene) and EcoRI/HindIII (for ltb gene) (Fer- 
mentas, Germany), respectively. The genes ampli- 
cons were cloned into pGH vector and then finally, 
lenA gene was subcloned into pET-15b, and lcpA and 
ltb genes sub-cloned into pET-28a expression vec- 
tors (Novagen, USA). The expression vectors were
http://ijm.tums.ac.ir 41 http://ijm.tums.ac.ir IRAN. J. MICROBIOL. Volume 11 Number 1 (February 2019) 39-47 
VACCINE PROTEINS OF LEPTOSPIRA INTERROGANS  
 
 
 
 
 
 
Table 1. List of primers used in study. 
 
Primer 
name 
Sequence (5' to 3') a Restriction 
Enzyme 
Amplicon 
size (bp)
 
LenA (F) GCCCCGGGCATATGATGAATTTAAAACAAGGAAATAAAA        SmaI, NdeI                 730 
LenA (R) GCCCCGGGCTCGAGCTGTTCTACACAGAGAAGATTTAG SmaI, XhoI  
LcpA (F) CCCGGGAAGCTTGCATGAGGAAGGAAATG SmaI, XhoI 647 
LcpA (R) GCCCCGGGCTCGAGACAGCCAGGACCTTCG SmaI, HindIII  
LTB (F) GCGATATCGAATTCGCTCCTCAGTCTATTACAGAACTA EcoRV, EcoRI 323 
LTB (R) GCGATATCCTCGAGGTTTTCCATACTGATTGCCGCAAT EcoRV, HindIII  
 
aArtificial restriction sites are underlined. 
 
 
 
confirmed both by restriction enzyme digestion and 
sequencing. 
The recombinant proteins were expressed in E. coli 
BL21 (DE3). Briefly, a single colony of transformed 
E. coli BL21 (DE3) containing pET-15b/lenA was 
cultured on 5 ml Luria Bertani (LB) broth contain- 
ing ampicillin (100 µg/mL) and incubated at 37°C 
overnight (about 16 h). Next day, 200 µl of overnight 
culture was transferred into 5 ml of LB broth con- 
taining ampicillin (100 µg/mL) at 37°C until the OD 
reached to 0.6 at 600 nm. Then a final concentration 
of 1 mM of IPTG (isopropyl-β-D-thiogalactopyrano- 
side) [Sigma-Aldrich] was added to bacterial cultures 
and the cells were grown for 4 hours at 37°C with 
constant shaking. The control cultures without IPTG 
induction were used. The bacterial cultures were 
centrifuged at 5,000 rpm for 5 minutes. The pellet 
and supernatant were transferred to separate tubes, 
and the cell pellets were suspended in 100 μl sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis 
(SDS-PAGE) sample loading buffer and were sub- 
jected to 12.5% SDS-PAGE. 
For purification of the recombinant protein, trans- 
formed E. coli BL21 (DE3) overexpressed in 500 ml 
Luria Bertani broth (Merck, Germany) containing 
ampicillin (100 µg/mL). The bacterial pellet was col- 
lected by centrifugation at 5000 rpm for 5 minutes 
and the supernatant discarded. The precipitate was 
dissolved in 5 ml lysis buffer (8 M urea, 100 mM 
NaH2PO4, 10 mMTris-HCl, pH: 8.0) and following 
centrifugation at 12000 rpm for 30 minutes. The su- 
pernatant loaded into Ni-NTA resin (Qiagen, Germa- 
ny) column and shaken gently for 1 hour. The column 
was washed six times with washing buffers (urea 8 
M, 6 M, 4 M, 2 M, 1 M and 0 M with pH:8.0). The re- 
combinant protein was then eluted using elution buf- 
fer (250 mM imidazole, 50 mM NaH2PO 4.300 mM 
NaCl, pH:8.0). Quality of protein purification was 
characterized by 12.5% SDS-PAGE method. The 
experiments similar to the described above, carried 
out for transformed E. coli BL21 (DE3) containing 
pET-28a/lcpA and pET-28a/ltb with kanamycin (50 
µg/mL) as a selectable marker. 
 
Western blotting. Western blotting carried out to 
establish protein expression using His-tag monoclo- 
nal antibody conjugated with horseradish peroxidase 
(HRP) (Thermo Fisher Scientific, Inc., Lithuania). 
The recombinant proteins were electrophoresed in 
12.5% polyacrylamide SDS gel and transferred onto 
PVDF membrane (Bio-Rad, Hercules, CA, USA) for 
90 min at 4°C. Membranes were blocked in PBS con- 
taining 3% skim milk and 0.05% Tween 20 at 4°C, 
overnight. After blocking, membranes were washed 
three times with PBS containing 0.05% Tween 20 
and then incubated with His-tag monoclonal anti- 
body conjugated with HRP (at 1:1000 dilution) for 1h 
at 25°C. Membranes were washed three times with 
PBS 1X containing 0.05% Tween 20 and then treat- 
ed with 3, 3’-diaminobenzidine solution (Sigma-Al- 
drich, USA) for about 3 min. 
 
Vaccine formulation. Protein concentrations were 
determined using the method of Bradford. The vac- 
cines were prepared in a proper proportion of recom- 
binant proteins of rLenA and rLcpA with rLTB as an 
adjuvant. In control group, the hamsters immunized 
with rLTB alone. The solutions were mixed gently 
for 4 h at 4°C and stored at 4°C until use. 
 
Hamster  model  of  leptospirosis.  Six  groups 
consist  of  fifteen female  Golden  Syrian  hamsters
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in each one, aged between 4 to 6 weeks, were used 
as the animal model. The vaccinated hamsters with 
the prepared protein compounds in this study, and a 
virulent isolate of L. interrogans serovar Copenha- 
geni strain Fiocruz L1-130 were used to determine 
challenge dose, as described previously (16). The 
hamsters were immunized in the quadriceps muscle 
twice, with a 14-day interval between each immuni- 
zation (days 0 and 14), as follows: rLenA-plus-LTB 
group, rLcpA-plus-LTB group, rLenA-plus-LcpA- 
plus-LTB group and LTB group (control). Two ad- 
ditional groups, Bacterin and PBS, as positive and 
negative control groups, respectively, accompanied 
with four groups which mentioned above, were con- 
sidered for challenge experiments. Thirty-four days 
after  the  first immunization,  all  of  six  groups  of 
hamsters were challenged intraperitoneally with 102 
cells of the virulent isolate of Leptospira. Before first 
immunization and challenge, serum of the hamsters 
was collected from the retro-orbital venous plexus 
after  administration  of  eye  anesthetic  drops,  and 
the sera were stored at -20°C, until further analyses. 
The hamsters were checked every day for mortality 
over a period of 21 days. Survivors were sacrificed 
21 days post challenge. All experiments were per- 
formed in accordance with animal handling proto- 
cols approved by the Institutional Animal Care and 
Use Committee. 
 
Antibody response determination using ELISA. 
The ELISA assay was performed using a commercial- 
ly available kit, 20 days after second immunization 
on sera from the vaccinated hamsters to determine 
Finally, optical density (OD) of mixtures was read at 
492 nm by ELISA Reader. 
 
Cytokine   determination.   The   concentrations 
of  IL-17,  IL-4  and  IFNγ  were  measured  by  en- 
zyme-linked immunosorbent assay. In brief, blood 
samples were collected from hamsters by eye bleed- 
ing after 16 h of the last immunization. Sera were 
separated from blood cells after coagulation at room 
temperature for 1 h and storage at 4°C for 1 h more 
with centrifugation at 12000 rpm for 10 min at room 
temperature. The samples were analyzed for IL-4, 
IL-17 and IFNγ using the sandwich ELISA assay 
according to the manufacturer’s recommendations 
(eBioscience, San Diego, CA). 
 
Statistical analysis. All of the Data were analyzed 
using SPSS software, version 22. Statistical Krus- 
kal–Wallis test was used to compare the significant 
differences among different groups. The significant 
differences among groups were further analyzed by 
post hoc tests. The p value < 0.05 statistically was 
considered significant. All of the curves and charts 
in this study, were drawed up using GraphPad Prism 
4 software. 
 
 
 
RESULTS 
 
Protein purification and western blotting anal- 
ysis. After induction of the transformed E. coli BL21 
(DE3) cells with IPTG as an inducer of gene expres- 
sion, all of the recombinant proteins expressed as in-
the total antibody, IgG and IgG a isotypes. Briefly, clusion bodies. For purification, we used denaturing,
the recombinant proteins (10 μg/mL) were adsorbed 
in PBS 1× buffer into 96-well polystyrene plates 
(Greinerbio-one, Fricken-hausen, Germany) over- 
night at 4°C. ELISA plates were washed three times 
with PBST (PBS with 0.05% [v/v] Tween 20) and then 
blocked with PBS containing 4% skim milk for 1 h 
at 25°C. The plates were then washed three times us- 
ing PBST, Hamster’s sera were added into the wells 
at dilutions of 1:100 to 1:12800, and incubated for 1 
h at 25°C. Following rinses, Peroxidase-conjugated 
anti-golden Syrian hamster IgG antibody (Rockland) 
was added at a 1:6,000 dilution and incubated for one 
hour at room temperature. The plates were washed 
five times with PBST, o-phenylenediamine dihy- 
drochloride (Sigma-Aldrich) substrate solution was 
added and the reaction was stopped with 4N H2SO4. 
re-naturing and eluting agents, respectively, and then 
yielded them as a soluble protein. The recombinant 
proteins were purified to near homogeneity by Ni- 
NTA chromatography. All three purified recombi- 
nant proteins were observed based on predicted size 
on the migration of SDS-PAGE gels (approximately 
30 kDa for rLenA, 29 kDa for rLcpA, and 17 kDa 
for rLTB). Also, these proteins reacted with the an- 
ti-His monoclonal antibody in Western blotting and 
appeared the intended bands (Figs. 1 and 2). 
 
Immune response in vaccinated hamsters. Hy- 
perimmune sera from the hamsters after the last 
booster injection were collected and titrated in all 
vaccinated groups by antigen-based ELISA. The 
highest OD in 492 nm (over 1:12800) of total IgG
http://ijm.tums.ac.ir 43 http://ijm.tums.ac.ir IRAN. J. MICROBIOL. Volume 11 Number 1 (February 2019) 39-47 
VACCINE PROTEINS OF LEPTOSPIRA INTERROGANS  
 
 
 
 
 
1 
2 
1 
2 
 
 
 
 
Fig. 1. Western blotting of purified rLTB (1), rLenA (2) and 
rLcpA (3) recombinant proteins. M: Protein size marker 
 
 
 
 
 
 
Fig. 2. Expression of rLenA, rLcpA and rLTB recombinant 
proteins in 12.5% gel M: Protein size marker, 1, 2 and 3 are 
rLTB, rLenA and rLcpA Proteins, respectively, after induc- 
tion. 
 
antibodies measured on the sera from the hamsters, 
was observed for rLenA-plus-rLcpA-plus-rLTB, rLe- 
nA-plus-rLTB, rLcpA-plus-rLTB, and rLTB groups, 
respectively. The rLenA-plus-rLcpA-plus-rLTB vac- 
cine  induced  significantly  higher  antibody  levels 
than the control group followed by rLenA-plus-rLTB 
( p<0.05). RLcpA-plus-rLTB and rLTB proteins did 
not induce any significant antibody response in vac- 
cinated hamsters ( p>0.05) (Fig. 3). The types of im- 
 
 
mune responses to the recombinant proteins were 
further examined by measuring the levels of IgG 
and IgG a subclasses. The hamsters inoculated with 
recombinant proteins had significantly higher IgG ti- 
ters than IgG a in comparison to control groups with 
a statistical significance ( p<0.05) (Fig. 4). 
 
Efficacy of vaccine preparations. The protective 
efficacy of the rLenA and rLcpA in combination 
with rLTB vaccine preparations were evaluated. The 
hamsters which were immunized with the mentioned 
protein compositions and also Bacterin and PBS 
(control) groups, were challenged with 102   cells of 
L. interrogans serovar Copenhageni strain Fiocruz 
L1-130, intraperitoneally injection. The hamsters 
immunized with the rLenA-plus-rLcpA-plus-rLTB, 
rLenA-plus-rLTB and rLcpA-plus-rLTB, showed 
statistically significant improvement ( p<0.05) in sur- 
vival rate after bacterial challenge (Fig. 5). The me- 
dian survival times for hamsters immunized with the 
recombinant proteins were significantly longer than 
hamsters received PBS alone ( p<0.05). The highest 
survival rate was observed in rLenA-plus-rLcpA- 
plus-rLTB group. 
 
Cytokine expression profile in immunized ham- 
sters. A significant amount of IL-17, IL-4 and IFNγ 
cytokines was produced in immunized hamsters 
(Fig. 6). There were not statistically significant dif- 
ferences ( p>0.05) between the groups. The levels 
of IFNγ in the immunized hamsters with rLenA- 
plus-rLcpA-plus-rLTB, rLenA-plus- rLTB and rLc- 
pA-plus-rLTB did not show statistically significant 
difference ( p>0.05) with group received rLTB alone. 
 
 
 
DISCUSSION 
 
Leptospira has a wide variety of mechanisms that 
enable it to evade the host immune system and en- 
hance the severity of the infection. The identification 
of protective antigens is needed to facilitate vac- 
cine-based prophylactic approaches. Some of identi- 
fied proteins contribute to the ability of the bacteria 
to adhere, invade and colonize onto the host tissues. 
Towards controlling the increasing problem of lep- 
tospirosis, for the first time we evaluated, LenA and 
LcpA proteins from L. interrogans serovar Copen- 
hageni strain Fiocruz L1-130 in combination with 
E. coli heat-labile enterotoxin, B subunit (LTB) as
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Fig. 3. Titration of Total IgG antibodies in sera of immunized hamsters. Twenty days after the last immunization serum sam- 
ples of the animals were collected and pooled. The sera were serially diluted and were coated on recombinant proteins. Differ- 
ent groups of animal seach consisting of 15 hamsters were administrated with either the rLenA, rLcpA and rLTB recombinant 
proteins. The titers of Total IgG antibodies were significantly high in hamsters (p<0.05). 
 
 
 
 
 
 
 
Fig. 4. Immunoglobulin isotyping assay in sera of immunized hamsters. Twenty days after the last immunization serum 
samples of the animals were collected and pooled. The sera were serially diluted and were coated on recombinant proteins. 
Different groups of animals each consisting of 15 hamsters were administrated with either the rLenA, rLcpA and rLTB re- 
combinant proteins. The IgG  levels were higher than IgG a levels in comparison to control group (LTB). The IgG  and IgG a 
1                                                                                2                                                                                                                                                             1                        2 
levels against rLcpA were lower than other proteins.
http://ijm.tums.ac.ir 45 http://ijm.tums.ac.ir IRAN. J. MICROBIOL. Volume 11 Number 1 (February 2019) 39-47 
VACCINE PROTEINS OF LEPTOSPIRA INTERROGANS  
 
 
 
 
 
 
 
 
 
 
Fig. 5. Cumulative survival rates of hamsters challenged with L. interrogans serovar Copenhageni strain Fiocruz L1-130. The 
hamsters were intraperitoneally infected with 102 cells of L. interrogans. The Survival rates of each group were checked for 21 
days. There were statistically significant differences (p<0.05) between immunized hamsters and control groups. 
 
 
 
 
 
Fig. 6. Levels of IL-4, IL-17 and IFNγ cytokines (pg/mL) in hamsters. The levels of IL-17 was very low compared to two other 
cytokines and did not show statistical differences with group that received rLTB alone (p>0.05). There were no statistically 
significant differences (p>0.05) between the groups. 
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potential candidates for vaccine production against 
Leptospiral infections. 
The available leptospiral vaccines are based on in- 
activated whole-cell or membrane preparation (18). 
However, these vaccines stimulate antibody respons- 
es, fail to induce immune memory and consequently 
require booster injections. Moreover, these vaccines 
bear considerable side-effects and do not provide 
cross-protective immunity against serovars (19, 20). 
Leptospiral   immunoglobulin-like   (Lig)   proteins 
are probably the best vaccine candidates, as they 
demonstrated 90-100% of protection in immunized 
hamsters that survived lethal bacterial challenge. 
However, these proteins are not conserved amongst 
all pathogenic strains and sterilizing immunity has 
not yet been achieved (21, 22), highlighting the need 
for new conserved antigens for development of a 
better vaccine. In the present study we evaluated 
two protein LenA and LcpA which are highly con- 
served among all pathogenic leptospires and could 
potentially confer cross-protection. However, these 
proteins showed lower protection (60-80%) in com- 
parison to Lig proteins. 
Our results showed that the rLenA and rLcpA pro- 
teins in combination with rLTB induce high IgG ti- 
ters in hamsters. Similar studies demonstrated that 
cell surface protein Lig could produce high IgG titers 
in hamsters (18). In another similar study conduct- 
ed by Oliveira et al., recombinant OmpL 37 induced 
a strong IgG response in hamsters inoculated with 
different vaccine formulations (21). In this study, re- 
combinant proteins were emulsified with rLTB as ad- 
juvant, which generated high titers of anti-LcpA and 
anti-LenA. A comparable study that used LTB along 
with recombinant protein LipL 32 showed signifi- 
cantly high titers against the leptospiral antigen (23). 
In this study, the plasma level of IFN gamma pro- 
duced in the hamsters immunized by rLenA and rL- 
cpA recombinant proteins was higher than IL-4 and 
IL-17. The high-level production of this cytokine in 
response to recombinant proteins may be due to the 
stimulation of Th-1 lymphocytes. Potent vaccine 
protection against leptospirosis has attributed to 
induction of Th-1 immune responses (23, 24). Sev- 
eral studies have reported that Th-1 and other com- 
ponents of innate immune systems are essential for 
bacterial clearance in animal models (24, 25). 
Results of present study revealed that the rLenA 
and rLcpA recombinant proteins efficiently stimu- 
lated cell mediated immunity. Our results predict that 
these proteins in combination with LTB recombinant 
have the potential for broad protective coverage 
against leptospiral infection. Both rLenA and rLcpA 
proteins can be used as candidate for vaccine devel- 
opment along with rLTB for better efficacy. Further 
investigation on the role of rLenA and rLcpAin li- 
gand binding and epitope mapping delineation might 
be necessary to further improvement of the lepto- 
spiral vaccines. Studies tailored towards identifying 
novel potential vaccine candidates against leptospi- 
ral infections are essential and still need. 
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